Cargando…

Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling

Background: Isocitrate dehydrogenase (IDH) mutations are the most common genetic aberrations in gliomagenesis. We aimed to build a high-efficiency prediction gene signature in patients with IDH-mutant glioma. Methods: In total, 167 gliomas from Chinese Glioma Genome Atlas (CGGA) dataset were include...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qiangwei, Wang, Zhiliang, Li, Guanzhang, Zhang, Chuanbao, Bao, Zhaoshi, Wang, Zheng, You, Gan, Jiang, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128431/ https://www.ncbi.nlm.nih.gov/pubmed/30115812 http://dx.doi.org/10.18632/aging.101521

Ejemplares similares

MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status
por: Li, Guanzhang, et al.
Publicado: (2018)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients
por: Zhao, Zheng, et al.
Publicado: (2021)

Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas
por: Cai, Jinquan, et al.
Publicado: (2016)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

A novel chemokine‐based signature for prediction of prognosis and therapeutic response in glioma
por: Fan, Wenhua, et al.
Publicado: (2022)

Comparative profiling of immune genes improves the prognoses of lower grade gliomas
por: Wang, Zhiliang, et al.
Publicado: (2022)

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
por: Liu, Yanwei, et al.
Publicado: (2022)

Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma
por: Dao Trong, Philip, et al.
Publicado: (2018)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Identification of an ATP metabolism‐related signature associated with prognosis and immune microenvironment in gliomas
por: Huang, Ruoyu, et al.
Publicado: (2020)

KIF23 is an independent prognostic biomarker in glioma, transcriptionally regulated by TCF-4
por: Sun, Lihua, et al.
Publicado: (2016)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors
por: Cai, Jinquan, et al.
Publicado: (2016)

An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas
por: Xiao, Gang, et al.
Publicado: (2021)

MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis
por: Yan, Wei, et al.
Publicado: (2014)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Molecular classification of IDH-mutant glioblastomas based on gene expression profiles
por: Wu, Fan, et al.
Publicado: (2019)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
por: Schenkel, Laila C., et al.
Publicado: (2022)

IDH mutation-specific radiomic signature in lower-grade gliomas
por: Liu, Xing, et al.
Publicado: (2019)

Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma
por: Chai, Rui-Chao, et al.
Publicado: (2019)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

A novel methylation signature predicts radiotherapy sensitivity in glioma
por: Feng, Yuemei, et al.
Publicado: (2020)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma
por: Liu, Shuai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_871o0ql4f90jf7fsma37vl8mro